OncoMatch/Clinical Trials/NCT04776525

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Is NCT04776525 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ifosfamide and Doxorubicin for soft tissue sarcoma.

Phase 2RecruitingOslo University HospitalNCT04776525Data as of May 2026

Treatment: Ifosfamide · Doxorubicin — Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.

Check if I qualify

Extracted eligibility criteria

Cancer type

Sarcoma

Disease stage

Grade: ≥ 2 (fnclcc)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any therapy for soft tissue sarcoma

Lab requirements

Blood counts

Hemoglobin ≥ 8.0 g/dL; Neutrophil count ≥ 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L

Kidney function

Creatinine clearance ≥ 60 ml/min based on Cockcroft Gault estimation or direct measurement

Liver function

Total bilirubin ≤ 1.5 x the upper limit of normal (ULN)

Cardiac function

Left ventricular ejection fraction (LVEF) ≥ 50%

Adequate organ function and bone marrow reserve as indicated by the following laboratory assessments: Hemoglobin ≥ 8.0 g/dL; Neutrophil count ≥ 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Total bilirubin ≤ 1.5 x the upper limit of normal (ULN); Creatinine clearance ≥ 60 ml/min based on Cockcroft Gault estimation or direct measurement. Left ventricular ejection fraction (LVEF) < 50% [excluded].

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify